Shareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Group 1 - The Ademi Firm is investigating Y-mAbs for possible breaches of fiduciary duty and other legal violations related to its transaction with SERB Pharmaceuticals [1] - In the tender offer, Y-mAbs shareholders will receive $8.60 per share in cash, totaling approximately $412 million in equity value [2] - The transaction agreement restricts competing offers for Y-mAbs by imposing a significant penalty if a competing bid is accepted, raising concerns about the board's fiduciary duties to shareholders [3]